The New York State Board of Pharmacy (NYBOP) has now formally confirmed its position on individual pharmacist licensure under New York’s shared pharmacy services law (Chapter 491 of the Laws of 2024), which takes effect May 22, 2026.
This confirmation follows initial guidance issued on December 31, 2025 during the rulemaking process, including materials presented to the New York Board of Regents, which signaled that pharmacists participating in shared services arrangements involving New York patients would be expected to hold New York licensure. Industry stakeholders quickly identified tension between that position and New York’s existing nonresident pharmacy framework, which historically regulates at the entity level rather than the individual pharmacist level.
In light of that apparent inconsistency, Quarles sought formal clarification from NYBOP. In a March 20, 2026 response to Quarles, the Board unequivocally confirmed its interpretation and, in doing so, effectively doubled down on its position that individual pharmacist licensure in New York is required to engage in shared services for New York patients.
Confirmed Position on Individual Pharmacist Licensure
Following the passage of A9729 (Chapter 491 of the Laws of 2024) and associated regulations, effective May 22, 2026, NYBOP takes the position that both the pharmacy and each individual pharmacist participating in shared pharmacy services must be registered in New York when servicing New York patients.
The Board’s interpretation is rooted in its reading of Education Law §§ 6802(30) and 6809, which it views as requiring that shared pharmacy services be performed only by “registered pharmacists or registered pharmacies.” NYBOP applies this requirement broadly, including to pharmacists employed by or contracted with nonresident pharmacies.
Importantly, NYBOP does not view this requirement as conflicting with New York’s nonresident pharmacy laws. Those laws generally require nonresident pharmacies to comply with the laws of their home state, subject to limited exceptions (e.g., controlled substances), rather than imposing full New York licensure requirements at the individual pharmacist level. See, e.g., N.Y. Comp. Codes R. & Regs. tit. 8 § 63.8(b)(5); N.Y. Educ. Law § 6808-b(4)(d).
The Board further confirmed that this requirement extends to remote and decentralized pharmacist activities. Even where services are performed outside of a licensed pharmacy setting, those activities fall within the definition of shared pharmacy services and therefore trigger New York registration requirements at the individual level.
Why This Matters
NYBOP’s confirmation solidifies a regulatory approach that is more restrictive than many in the industry anticipated and departs from how several other states treat shared services and nonresident pharmacy activity.
For pharmacies serving New York patients, the implications are immediate and operational:
Organizations must evaluate whether pharmacists supporting New York workflows, including remote personnel, hold New York licensure.
National and hub-based models may face increased friction in staffing and scalability.
Existing compliance assumptions based solely on nonresident pharmacy licensure are no longer sufficient.
More broadly, this position raises ongoing questions about regulatory consistency and the practical limits of state-by-state pharmacist licensure in an increasingly centralized and technology-enabled dispensing environment.
Bottom Line
NYBOP has now confirmed that individual pharmacist licensure is required for shared pharmacy services involving New York patients. Pharmacies should move quickly to assess their models, identify any licensure gaps, and implement necessary changes ahead of the May 22, 2026 effective date.
Quarles will continue to monitor developments and engage with regulators as appropriate. If you would like to discuss the impact of this guidance on your operations, please contact your Quarles attorney or: